Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT

This study tests whether transferring specialised immune cells (called CMV-specific cytotoxic T lymphocytes or CTLs) from a stem cell donor to a patient who has received a stem cell transplant can prevent or treat cytomegalovirus (CMV) infection. CMV is a common virus that can cause serious illness in people with weakened immune systems after transplant. You may be eligible if: - You have received an allogeneic (donor) blood stem cell transplant - It has been more than 28 days since your transplant - Your donor is HLA-A*0201 positive and CMV positive - You had a matched sibling donor (5/6 or 6/6 match) or a 6/6 matched unrelated donor - Your graft-versus-host disease (GVHD) is less than grade II at the time of infusion - You have not recently received anti-lymphocyte therapy You may NOT be eligible if: - There are no additional specific exclusion criteria listed beyond meeting the above requirements Talk to your doctor about whether this trial might be right for you.